MECFA Blog

News & Articles

NuvoAir Launches Air Next, Revolutionary New Home Device to Help Those With Serious Lung Conditions

STOCKHOLM, April 18, 2018 /PRNewswire/ -- The latest version of a hand-held device to help people improve the self-management of ongoing lung conditions is being launched this month. With its use of Bluetooth wireless technology, the new Air Next is among the world's most advanced home-use spirometers. Spirometers are devices that allow users to measure how well their lungs are performing. This new spirometer has been developed by Swedish digital health start-up company NuvoAir. It's a major step forward from its previous device, the Air Smart Spirometer, which has been available since 2016. The Air Next itself is a sleek design that fits into the palm of the hand. However, its manufacturer

MVW Nutritionals® and Lutrish Partner to Expand Nutritional Options for the Cystic Fibrosis Communit

Effective today, MVW Nutritionals is pleased to announce a partnership with the makers of Lutrish that enables CF Center Team Members and patients to make just one phone call to address nutritional needs. While increasing convenience for patients, it also shifts the administrative work involved in ordering, patient follow-up and refill management from CF Center team members to us, while enabling the Companies to reduce overall product cost and the cost of nutritional care. HUNTSVILLE, Ala. (PRWEB) April 21, 2018 "While it's well accepted that effective nutrition remains a cornerstone in CF care, and with almost half of the 30,000 patients with cystic fibrosis receiving oral supplemental nutr

Lung Stem Cells Discovery in Mice May Benefit Cystic Fibrosis Treatment

A new population of lung stem cells capable of repairing the airways following a severe injury was identified in two preclinical studies. These cells’ ability to transform and replace several lung cell types may be explored for regenerative medicines to treat diseases such as cystic fibrosis. The findings were reported in two independent studies, “Myoepithelial Cells of Submucosal Glands Can Function as Reserve Stem Cells to Regenerate Airways after Injury” and “Submucosal Gland Myoepithelial Cells Are Reserve Stem Cells That Can Regenerate Mouse Tracheal Epithelium,” both published in the journal Cell Stem Cell. Stem cells have the capacity to differentiate into many cell types, as well as

Orkambi’s Components Trigger Liver Enzyme That Decreases Its Ability to Fight CF, Study Finds

The two components of Orkambi act separately to trigger a liver enzyme that decreases the therapy’s ability to fight cystic fibrosis, a study reported. Vertex Pharmaceuticals created Orkambi by combining ivacaftor and lumacaftor (VX-809). It addresses the underlying cause of the disease — a gene mutation that leads to a build-up of thick mucus in the lungs and other problems. Researchers’ study about the liver enzyme problem appeared in the journal Drug Metabolism Letters. The title is “Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor.” The U.S. Food and Drug Administration approved Orkambi in Septemb

Abnormal Glucose Levels Linked to Poorer Lung Function in Cystic Fibrosis Youth, Study Shows

Abnormalities in continuous glucose monitoring (CGM) measures correlate with a decline in lung function in children and adolescents with cystic fibrosis (CF), a study suggests. The study, “Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline,” was published in the Journal of Cystic Fibrosis. CF-related diabetes (CFRD) is the most frequent condition that occurs in cystic fibrosis patients, affecting up to 20 percent of adolescents and 50 percent of adults. The prevalence of CFRD increases after age 10, which is when current CF guidelines recommend using an oral glucose tolerance test (OGTT) for annual diabetes screening. These guidelin

Bacteria Can Pass Memory of Biofilm Formation to Descendants, Study Shows

Bacteria can transmit memory across generations so their descendants will know how to attach themselves to surfaces and form communities called biofilms, a study reports. Researchers’ findings shed light on cystic fibrosis-related bacteria’s early steps in biofilm formation. These pathogens cause persistent airway infections in people with the disease. The study, “Multigenerational memory and adaptive adhesion in early bacterial biofilm communities,” was published in the journal Proceedings of the National Academy of Sciences. Researchers at UCLA and colleagues focused their study on a bacteria commonly found in CF patients’ airway — Pseudomonas aeruginosa. It grows into biofilms, or densely

Bacteria have a ‘memory’ they pass from one generation to the next, say UCLA scientists

Pseudomonas aeruginosa bacteria is seen in an image by Wikimedia Commons user HansN. UCLA researchers have determined that such bacteria possess a form of “memory” that can pass between generations. (Image reproduced under the CC-BY-SA-3.0 license) LOS ANGELES — An international team of researchers led by UCLA scientists has discovered that bacteria have a “memory” that passes sensory knowledge from one generation of cells to the next, all without a central nervous system or any neurons, UCLA reported today. “This is a huge surprise to us and to the field,” said Gerard Wong, a professor of bioengineering and of chemistry and biochemistry, member of the California NanoSystems Institute at UCL

2 Urine Biomarkers Can Help Detect Aminoglycosides-induced Kidney Damage in CF Patients, Study Sugge

Quantification of two specific molecules in urine can help in the early detection of kidney damage triggered by treatment with aminoglycosides in patients with cystic fibrosis (CF), a study suggests. This finding was reported in the study “Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin,” published in the journal Scientific Reports. Antibiotics in the group of aminoglycosides are commonly used to manage acute pulmonary exacerbations and Pseudomonas aeruginosa infections in patients with CF. Despite their therapeutic activity, aminoglycosides can promote damage to the kidneys. Indeed, expos

Proteostasis Therapeutics Wins Big With FDA Decision

Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares made a solid gain on Wednesday after a key U.S. Food and Drug Administration (FDA) decision was announced. This is yet again proof that the FDA has the potential to make and break companies in the biopharma industry. The FDA has granted Fast Track Designation for the company’s triple combination program for the treatment of cystic fibrosis. The proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator (CFTR) amplifier, third generation corrector and potentiator, known as PTI-428, PTI-801 and PTI-808, respectively. Back in January, Proteostasis announced that the protocol for its triple combination c

Many CF Patients Have Long-term Staphylococcus Aureus Infections, Study Shows

Many cystic fibrosis patients have long-term Staphylococcus aureus infections, with the bacteria’s resistance to antibiotics fluctuating over time, a study reports. Chronic and recurrent infection of the airways is the most severe consequence of cystic fibrosis. The most prevalent bacteria is Staphylococcus aureus. There are different types of it, however, and studies have not looked extensively at which types cause the most damage over the long term. Previous studies have shown that small colony variants (SCVs) and methicillin-resistant S. aureus (MRSA) have the most severe impact on CF patients’ lung function. But few studies have looked at S. aureus infections’ long-term effect on lung fu

GeneFo Releases Updated 2018 Guide to Help Cystic Fibrosis Patients Navigate Treatment Options

GeneFo has put together an updated 2018 guide on treatment options for people with cystic fibrosis (CF) after recent developments again focused attention on the high price tag of some of these medications and the difficulties patients face in accessing them. The guide includes information on financial and clinical resources to help patients afford cystic fibrosis medications, such as assistance funds, clinical programs, and free insurance counseling/tax reduction programs, as well as access programs that provide free treatments in return for patient feedback. Patients and members of the medical community have voiced their frustration at the high costs of cystic fibrosis treatments, especiall

Proteostasis Therapeutics' FDA Breakthrough Therapy Designation Gives It An Edge

Summary * Proteostasis Therapeutics obtains breakthrough therapy designation from the FDA based on positive data from a phase 2 trial with PTI-428 treating cystic fibrosis. * PTI-428 and all other candidates in Proteostasis' pipeline are being developed as both monotherapy and combinations which provides for more potential upside. * Financials are good for now, but it is highly likely that the company will have to raise cash towards the end of 2018. Recently, Proteostasis Therapeutics (PTI) announced some highly positive news. It announced that the FDA had granted its lead drug PTI-428 for cystic fibrosis with a breakthrough therapy designation. I like this biotech because I believe it of

Featured Posts
Recent Posts
Archive
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean